Improving survival outcomes with systemic therapy in advanced hepatocellular carcinoma

02 Apr 2021
Improving survival outcomes with systemic therapy in advanced hepatocellular carcinoma
At the 3rd Bayer Hepatocellular Carcinoma (HCC) Masterclass, three distinguished speakers shared their insights into the management of intermediate and advanced HCC in Malaysia. Topics discussed include current treatment landscape and updates in disease management, as well as two case studies that highlighted the role of tyrosine kinase inhibitors (TKIs) in improving the overall survival (OS) of patients with advanced HCC.

Related MIMS Drugs

Editor's Recommendations